Approved for FORZINITY is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication is approved under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint. Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.. FORZINITY…
Loading full data from Know Your Drugs Institute…